Editas medicine stock price.

Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 03. CI. North American Morning Briefing : S&P 500 Futures -2-. Nov. 03. DJ. Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored ...

Editas medicine stock price. Things To Know About Editas medicine stock price.

Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85. The forecasts range from a low of $7.00 to a high of $30.00. The average ...Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 17.03% so far this month. During the month of May, Editas Medicine Inc’s stock price has reached a high of $10.71 and a low of $7.69. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas Medicine ...intraday 1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Friday 12/01/2023 the closing price of the Editas …

Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET ... What happened. Shares of Editas Medicine ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics.The average price targets for Editas Medicine and Intellia Therapeutics are $13.18 and $83.75, respectively, according to Yahoo! Finance. That implies an upside of about 54% for the former and 119 ...

Sep 29, 2023 · Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. ... Shares of Editas Medicine (EDIT 2.28%) ...

Editas Medicine has granted the underwriters a 30-day op ... today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 ...View Editas Medicine, Inc EDIT investment & stock information. Get the latest Editas Medicine, Inc EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Price as of December 1, 2023, 4:00 p.m. ET ... This fact has led to a stomach-churning level of volatility among stocks tied to CRISPR and related forms of gene ... Editas …Editas Medicine, Inc. (EDIT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Editas Medicine, Inc. | Nasdaq: EDIT | Nasdaq …Nov 20, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 62.28% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $11.14 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ...

Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...

The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.

Editas Medicine is a CRISPR company based out of Cambridge, Massachusetts, working "to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines " At the ...Editas Medicine stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics Motley Fool - Mon Oct 2, 9:00AM CDT . The better of the pair should be able to beat Bluebird Bio. EDIT: 10.77 (+2.28%) CRSP: 68.65 (+2.88%) Why Editas …What's Happening With Editas Medicine Inc Stock Today? Editas Medicine Inc (EDIT) stock is up 0.19% while the S&P 500 has fallen -0.91% as of 11:28 AM on …Jun 28, 2023 · Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ... The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Nonetheless, the filing did say that Editas already raised $163.3 million from selling preferred stock to private investors like Bill Gates and Google Ventures, along with other backers like Sun ...

For example, Editas Medicine (EDIT 11.37%) and Exact Sciences (EXAS 7.07%) fell by 66.5% and 36.4% respectively over the course of 2022. Since the change in the calendar year, Editas stock has ...Editas Medicine saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 16,770,000 shares, an increase of 2.1% from the previous total of 16,420,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are ...Editas Medicine's cash burn of US$181m is about 36% of its US$503m market capitalisation. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's ...CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.Find the latest Editas Medicine, Inc. (8EM.F) stock quote, history, news and other vital information to help you with your stock trading and investing.Editas Medicine, Inc. (EDIT) Stock Forecast & Price Targets - Stock Analysis NASDAQ: EDIT · IEX Real-Time Price · USD Add to Watchlist 10.75 +0.22 …

Editas Medicine ended the third quarter with $478.5 million in cash and equivalents, compared to $657 million as of Q3 2021. It reported a net loss of $55.7 million during the period, worse than ...

In the last 3 months, 18 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $19.17 with a high of $43.00 and a low of $6.00.10.68 BATS BZX Real-Time Price As of 3:23pm ET +0.15 / +1.42% Today’s Change 6.08 Today ||| 52-Week Range 11.93 +20.41% Year-to-Date Quote Profile News Charts Forecasts Financials Shareholders...Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions. Editas Medicine Inc () Stock Market info Recommendations: Buy or sell Editas Medicine stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below.According to present data Editas Medicine's EDIT shares and potentially its market environment …Apr 17, 2023 · Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ... CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …

Price of Stock Editas Medicine (EDIT) Today.

For example, Editas Medicine (EDIT 11.37%) and Exact Sciences (EXAS 7.07%) fell by 66.5% and 36.4% respectively over the course of 2022. Since the change in the calendar year, Editas stock has ...

Editas Medicine (EDIT) stock price prediction is 21.694681385149 USD. The Editas Medicine stock forecast is 21.694681385149 USD for 2024 November 30, ...Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 17.81% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $9.06 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $13.94 and as low as $6.08. Year to date, Editas ...Dec 1, 2023 · 12 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price. Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 13.39% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.48. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.71. Year to date, Editas ...Research Editas Medicine's (Nasdaq:EDIT) stock key valuation metrics while comparing it with its industry peers & market side by side. ... The above table shows the analyst EDIT forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$10 ...Editas Medicine stock declined 13% over a 5-day trading period ending 1/21/2021, compared to broader market (S&P500) rise of 1.3%. A change of -13% or more over 5 trading days is a 6% likelihood ...North American Morning Briefing : Stock Futures, -2- Oct. 02: DJ Stifel Upgrades Editas Medicine to Buy From Hold, Adjusts Price Target to $17 From $9 ... Chardan Cuts Price Target on Editas Medicine to $19 From $22, Maintains Buy Rating Aug. 03: MT Transcript : Editas Medicine, Inc., Q2 2023 Earnings Call, Aug 02, 2023 …Editas Medicine (EDIT 4.03%) ... Could Editas Medicine be a millionaire-maker stock over the next 10 to 20 years? ... Stock Advisor list price is $199 per year.Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geulah Livshits from Chardan Capital remains neutral on the stock ...Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 03. CI. North American Morning Briefing : S&P 500 Futures -2-. Nov. 03. DJ. Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored ...

Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.Editas Medicine stock price target cut to $35 from $80 at Truist Nov. 18, 2022 at 7:08 a.m. ET by Tomi Kilgore Editas Medicine started at neutral with $18 stock price target at …Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.11 Ago 2021 ... The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise ...Instagram:https://instagram. avawatz stockmusic nft marketplacehazard insurance commercialrepublic stock The stock option provides for the purchase of up to 123,350 shares of Editas Medicine common stock at a price of $8.00 per share, the closing price per share of Editas Medicine common stock as ... average brokerage feesstock dip Editas Medicine closed an underwritten offering of 4,025,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. This included 525,000 shares issued upon exercise in full by the underwriters of their option to purchase additional shares.EDIT Editas Medicine Inc. 10.57 -0.15 ( -1.40%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats. horse insurance reviews Editas Medicine's (NASDAQ: EDIT) lead candidate, EDIT-101, is a gene-editing therapy that targets a rare genetic disease called Leber congenital amaurosis 10, which leads to progressive blindness ...This might seem like deja vu. Editas Medicine ( EDIT 11.39%) shares soared on Monday. Then on Tuesday. And on Wednesday. The stock is on fire again today, skyrocketing 22.3% as of 11:09 a.m. EST ...